Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle R Mahoney

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
American Journal of Clinical Oncology|June 11, 2003
Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancersPaul L Schaefer, Randolph S Marks, Michelle R Mahoney, et al.
Journal of the American College of Surgeons|April 30, 2013
Current use and surgical efficacy of laparoscopic colectomy in colon cancerRobert P Sticca, Steven R Alberts, Michelle R Mahoney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2005
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II studySteven R Alberts, William L Horvath, William C Sternfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2013
Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapyFrank A Sinicrope, Michelle R Mahoney, Thomas C Smyrk, et al.
Clinical Colorectal Cancer|July 7, 2011
Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52John S Bolton, Michael J O'Connell, Michelle R Mahoney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2014
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance)Harry H Yoon, David Tougeron, Qian Shi, et al.
Cancer|November 24, 2004
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trialSteven R Alberts, Hani Al-Khatib, Michelle R Mahoney, et al.
The Lancet. Oncology|January 27, 2018
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trialsSandra P D'Angelo, Michelle R Mahoney, Brian A Van Tine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841George P Kim, Daniel J Sargent, Michelle R Mahoney, et al.
Investigational New Drugs|September 15, 2010
An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinomaGeorge P Kim, Michelle R Mahoney, Daniel Szydlo, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
American Journal of Clinical Oncology|June 11, 2003
Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancersPaul L Schaefer, Randolph S Marks, Michelle R Mahoney, et al.
Journal of the American College of Surgeons|April 30, 2013
Current use and surgical efficacy of laparoscopic colectomy in colon cancerRobert P Sticca, Steven R Alberts, Michelle R Mahoney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2005
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II studySteven R Alberts, William L Horvath, William C Sternfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2013
Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapyFrank A Sinicrope, Michelle R Mahoney, Thomas C Smyrk, et al.
Clinical Colorectal Cancer|July 7, 2011
Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52John S Bolton, Michael J O'Connell, Michelle R Mahoney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2014
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance)Harry H Yoon, David Tougeron, Qian Shi, et al.
Cancer|November 24, 2004
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trialSteven R Alberts, Hani Al-Khatib, Michelle R Mahoney, et al.
The Lancet. Oncology|January 27, 2018
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trialsSandra P D'Angelo, Michelle R Mahoney, Brian A Van Tine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841George P Kim, Daniel J Sargent, Michelle R Mahoney, et al.
Investigational New Drugs|September 15, 2010
An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinomaGeorge P Kim, Michelle R Mahoney, Daniel Szydlo, et al.
Pageof 5